Yue Zhang1, Kai Han1, Chunjing Du2, Rui Li1, Jingyuan Liu2, Hui Zeng3, Liuluan Zhu4, Ang Li5. 1. Beijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China. 2. Department of Critical Care Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China. 3. Beijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China. zenghui@ccmu.edu.cn. 4. Beijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China. zhuliuluan@ccmu.edu.cn. 5. Department of Critical Care Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China. liang@ccmu.edu.cn.
Abstract
BACKGROUND: Thrombosis and coagulopathy are highly prevalent in critically ill patients with COVID-19 and increase the risk of death. Immunothrombosis has recently been demonstrated to contribute to the thrombotic events in COVID-19 patients with coagulopathy. As the primary components of immunothrombosis, neutrophil extracellular traps (NETs) could be induced by complement cascade components and other proinflammatory mediators. We aimed to explore the clinical roles of NETs and the regulation of complement on the NET formation in COVID-19. METHODS: We recruited 135 COVID-19 patients and measured plasma levels of C5, C3, cell-free DNA and myeloperoxidase (MPO)-DNA. Besides, the formation of NETs was detected by immunofluorescent staining and the cytotoxicity to vascular endothelial HUVEC cells was evaluated by CCK-8 assay. RESULTS: We found that the plasma levels of complements C3 and MPO-DNA were positively related to coagulation indicator fibrin(-ogen) degradation products (C3: r = 0.300, p = 0.005; MPO-DNA: r = 0.316, p = 0.002) in COVID-19 patients. Besides, C3 was positively related to direct bilirubin (r = 0.303, p = 0.004) and total bilirubin (r = 0.304, p = 0.005), MPO-DNA was positively related to lactate dehydrogenase (r = 0.306, p = 0.003) and creatine kinase (r = 0.308, p = 0.004). By using anti-C3a and anti-C5a antibodies, we revealed that the complement component anaphylatoxins in the plasma of COVID-19 patients strongly induced NET formation. The pathological effect of the anaphylatoxin-NET axis on the damage of vascular endothelial cells could be relieved by recombinant carboxypeptidase B (CPB), a stable homolog of enzyme CPB2 which can degrade anaphylatoxins to inactive products. CONCLUSIONS: Over-activation in anaphylatoxin-NET axis plays a pathological role in COVID-19. Early intervention in anaphylatoxins might help prevent thrombosis and disease progression in COVID-19 patients.
BACKGROUND:Thrombosis and coagulopathy are highly prevalent in critically illpatients with COVID-19 and increase the risk of death. Immunothrombosis has recently been demonstrated to contribute to the thrombotic events in COVID-19patients with coagulopathy. As the primary components of immunothrombosis, neutrophil extracellular traps (NETs) could be induced by complement cascade components and other proinflammatory mediators. We aimed to explore the clinical roles of NETs and the regulation of complement on the NET formation in COVID-19. METHODS: We recruited 135 COVID-19patients and measured plasma levels of C5, C3, cell-free DNA and myeloperoxidase (MPO)-DNA. Besides, the formation of NETs was detected by immunofluorescent staining and the cytotoxicity to vascular endothelial HUVEC cells was evaluated by CCK-8 assay. RESULTS: We found that the plasma levels of complements C3 and MPO-DNA were positively related to coagulation indicator fibrin(-ogen) degradation products (C3: r = 0.300, p = 0.005; MPO-DNA: r = 0.316, p = 0.002) in COVID-19patients. Besides, C3 was positively related to direct bilirubin (r = 0.303, p = 0.004) and total bilirubin (r = 0.304, p = 0.005), MPO-DNA was positively related to lactate dehydrogenase (r = 0.306, p = 0.003) and creatine kinase (r = 0.308, p = 0.004). By using anti-C3a and anti-C5a antibodies, we revealed that the complement component anaphylatoxins in the plasma of COVID-19patients strongly induced NET formation. The pathological effect of the anaphylatoxin-NET axis on the damage of vascular endothelial cells could be relieved by recombinant carboxypeptidase B (CPB), a stable homolog of enzyme CPB2 which can degrade anaphylatoxins to inactive products. CONCLUSIONS: Over-activation in anaphylatoxin-NET axis plays a pathological role in COVID-19. Early intervention in anaphylatoxins might help prevent thrombosis and disease progression in COVID-19patients.
Authors: Chiara Cerletti; Chiara Tamburrelli; Benedetta Izzi; Francesco Gianfagna; Giovanni de Gaetano Journal: Thromb Res Date: 2011-11-09 Impact factor: 3.944
Authors: Bernadette Schurink; Eva Roos; Teodora Radonic; Ellis Barbe; Catherine S C Bouman; Hans H de Boer; Godelieve J de Bree; Esther B Bulle; Eleonora M Aronica; Sandrine Florquin; Judith Fronczek; Leo M A Heunks; Menno D de Jong; Lihui Guo; Romy du Long; Rene Lutter; Pam C G Molenaar; E Andra Neefjes-Borst; Hans W M Niessen; Carel J M van Noesel; Joris J T H Roelofs; Eric J Snijder; Eline C Soer; Joanne Verheij; Alexander P J Vlaar; Wim Vos; Nicole N van der Wel; Allard C van der Wal; Paul van der Valk; Marianna Bugiani Journal: Lancet Microbe Date: 2020-09-25
Authors: Zachary Grimes; Clare Bryce; Emilia Mia Sordillo; Ronald E Gordon; Jason Reidy; Alberto E Paniz Mondolfi; Mary Fowkes Journal: Cardiovasc Pathol Date: 2020-05-12 Impact factor: 2.185
Authors: F A Klok; M J H A Kruip; N J M van der Meer; M S Arbous; D Gommers; K M Kant; F H J Kaptein; J van Paassen; M A M Stals; M V Huisman; H Endeman Journal: Thromb Res Date: 2020-04-30 Impact factor: 3.944
Authors: Elizabeth A Middleton; Xue-Yan He; Frederik Denorme; Robert A Campbell; David Ng; Steven P Salvatore; Maria Mostyka; Amelia Baxter-Stoltzfus; Alain C Borczuk; Massimo Loda; Mark J Cody; Bhanu Kanth Manne; Irina Portier; Estelle S Harris; Aaron C Petrey; Ellen J Beswick; Aleah F Caulin; Anthony Iovino; Lisa M Abegglen; Andrew S Weyrich; Matthew T Rondina; Mikala Egeblad; Joshua D Schiffman; Christian Con Yost Journal: Blood Date: 2020-09-03 Impact factor: 25.476
Authors: Diana A Gorog; Robert F Storey; Paul A Gurbel; Udaya S Tantry; Jeffrey S Berger; Mark Y Chan; Daniel Duerschmied; Susan S Smyth; William A E Parker; Ramzi A Ajjan; Gemma Vilahur; Lina Badimon; Jurrien M Ten Berg; Hugo Ten Cate; Flora Peyvandi; Taia T Wang; Richard C Becker Journal: Nat Rev Cardiol Date: 2022-01-13 Impact factor: 49.421
Authors: Matthew A Scott; Amelia R Woolums; Cyprianna E Swiderski; Alexis C Thompson; Andy D Perkins; Bindu Nanduri; Brandi B Karisch; Dan R Goehl Journal: BMC Vet Res Date: 2022-02-23 Impact factor: 2.741
Authors: Endry Hartono Taslim Lim; Rombout Benjamin Ezra van Amstel; Vieve Victoria de Boer; Lonneke Alette van Vught; Sanne de Bruin; Matthijs Christian Brouwer; Alexander Petrus Johannes Vlaar; Diederik van de Beek Journal: Blood Rev Date: 2022-07-30 Impact factor: 10.626
Authors: Maximilian Ackermann; Hans-Joachim Anders; Rostyslav Bilyy; Gary L Bowlin; Christoph Daniel; Rebecca De Lorenzo; Mikala Egeblad; Timo Henneck; Andrés Hidalgo; Markus Hoffmann; Bettina Hohberger; Yogendra Kanthi; Mariana J Kaplan; Jason S Knight; Jasmin Knopf; Elzbieta Kolaczkowska; Paul Kubes; Moritz Leppkes; Aparna Mahajan; Angelo A Manfredi; Christian Maueröder; Norma Maugeri; Ioannis Mitroulis; Luis E Muñoz; Teluguakula Narasaraju; Elisabeth Naschberger; Indira Neeli; Lai Guan Ng; Marko Z Radic; Konstantinos Ritis; Patrizia Rovere-Querini; Mirco Schapher; Christine Schauer; Hans-Uwe Simon; Jeeshan Singh; Panagiotis Skendros; Konstantin Stark; Michael Stürzl; Johan van der Vlag; Peter Vandenabeele; Ljubomir Vitkov; Maren von Köckritz-Blickwede; Cansu Yanginlar; Shida Yousefi; Alexander Zarbock; Georg Schett; Martin Herrmann Journal: Cell Death Differ Date: 2021-05-24 Impact factor: 15.828